Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tania Setiawan has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Hyog Young Kwon

    Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan-si 31151, Republic of Korea; Soonchunhyang Institute of Medi-bio Science (SIMS), Soonchunhyang University, Cheonan-si 31151, Republic of Korea

    8 shared publications
  • Ita Novita Sari

    Soonchunhyang Institute of Medi-bio Science (SIMS), Soonchunhyang University, Cheonan-si, Republic of Korea

    4 shared publications
  • Jabir Aliyu Muhammad

    Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan-si 31151, Republic of Korea

    4 shared publications
  • Nadya Marcelina Julianto

    Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan-si, Republic of Korea; Soonchunhyang Institute of Medi-bio Science (SIMS), Soonchunhyang University, Cheonan-si, Republic of Korea

    4 shared publications
  • Lawrence Mario Wirawan

    Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan-Si, Republic of Korea

    3 shared publications
  • Yoseph Toni Wijaya

    Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan-Si, Republic of Korea

    3 shared publications

Latest Publications

  • Renal Aging and Associated Diseases: Common Mechanisms and Therapeutic Approaches

    by Jabir Aliyu Muhammad, Nadya Marcelina Julianto, Tania Setiawan, Teresa Fiona Fadjaray, Fernando Elbert, Mudasir Hussain, Lawrence Mario Wirawan, Dongjun Jeong, Hyog Young Kwon

  • Ginsenoside Rd attenuates renal aging and fibrosis through inhibition of angiotensin II type 1 receptor signaling

    by Tania Setiawan, Nadya Marcelina Julianto, Yoseph Toni Wijaya, Teresa Fiona Fadjaray, Lawrence Mario Wirawan, Jabir Aliyu Muhammad, Charuvaka Muvva, Keunwan Park, Soo Wan Kim, Eun Young Lee, et al.


  • Open Access

    Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis

    by Tania Setiawan, Jabir Aliyu Muhammad, Nadya Marcelina Julianto, Lawrence Mario Wirawan, Nayoung Jun, Ita Novita Sari, Vivian G. Oehler, Dong-Wook Kim, Hyog Young Kwon

  • Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis

    by Tania Setiawan, Jabir Aliyu Muhammad, Nadya Marcelina Julianto, Lawrence Mario Wirawan, Nayoung Jun, Ita Novita Sari, Vivian G. Oehler, Dong-Wook Kim, Hyog Young Kwon

    Amino acid homeostasis is critical for leukemic cell survival, with the mTOR pathway playing a central role in sensing and responding to nutrient availability. DEPTOR, a component and negative regulator of mTOR complexes, has been extensively studied in solid tumors and multiple myeloma, but its role in acute myeloid leukemia (AML) remains unclear. Here, we identify DEPTOR as a key regulator of leukemia progression through its interaction with KIF11. DEPTOR expression is transcriptionally induced by ATF4 and post-transcriptionally stabilized by MSI2, which binds to DEPTOR mRNA and prevents its degradation. DEPTOR is highly expressed in leukemia stem cells (LSCs) and is associated with poor clinical outcomes. Functionally, DEPTOR loss impairs leukemogenesis in both AML and blast phase chronic myeloid leukemia (bpCML) models, without affecting normal hematopoietic stem cells. Mechanistically, DEPTOR stabilizes KIF11 by preventing its ubiquitination and proteasomal degradation, thereby ensuring proper mTORC1 localization and metabolic adaptation during nutrient stress. Collectively, our findings establish the MSI2/DEPTOR/KIF11 axis as a critical driver of leukemogenesis and a promising therapeutic target for aggressive myeloid leukemias.


  • Top Cited Papers
    Open Access

    Cancer cachexia: molecular mechanisms and treatment strategies

    by Tania Setiawan, Ita Novita Sari, Yoseph Toni Wijaya, Nadya Marcelina Julianto, Jabir Aliyu Muhammad, Hyeok Lee, Ji Heon Chae, Hyog Young Kwon

    Muscle wasting is a consequence of physiological changes or a pathology characterized by increased catabolic activity that leads to progressive loss of skeletal muscle mass and strength. Numerous diseases, including cancer, organ failure, infection, and aging-associated diseases, are associated with muscle wasting. Cancer cachexia is a multifactorial syndrome characterized by loss of skeletal muscle mass, with or without the loss of fat mass, resulting in functional impairment and reduced quality of life. It is caused by the upregulation of systemic inflammation and catabolic stimuli, leading to inhibition of protein synthesis and enhancement of muscle catabolism. Here, we summarize the complex molecular networks that regulate muscle mass and function. Moreover, we describe complex multi-organ roles in cancer cachexia. Although cachexia is one of the main causes of cancer-related deaths, there are still no approved drugs for cancer cachexia. Thus, we compiled recent ongoing pre-clinical and clinical trials and further discussed potential therapeutic approaches for cancer cachexia.


  • Open Access

    Ginsenoside Rd ameliorates muscle wasting by suppressing the signal transducer and activator of transcription 3 pathway

    by Yoseph Toni Wijaya, Tania Setiawan, Ita Novita Sari, Keunwan Park, Chan Hee Lee, Kae Won Cho, Yun Kyung Lee, Jae‐Young Lim, Jeong Kyo Yoon, Sae Hwan Lee, et al.

    Background: The effects of some drugs, aging, cancers, and other diseases can cause muscle wasting. Currently, there are no effective drugs for treating muscle wasting. In this study, the effects of ginsenoside Rd (GRd) on muscle wasting were studied.Methods: Tumour necrosis factor‐alpha (TNF‐α)/interferon‐gamma (IFN‐γ)‐induced myotube atrophy in mouse C2C12 and human skeletal myoblasts (HSkM) was evaluated based on cell thickness. Atrophy‐related signalling, reactive oxygen species (ROS) level, mitochondrial membrane potential, and mitochondrial number were assessed. GRd (10 mg/kg body weight) was orally administered to aged mice (23–24 months old) and tumour‐bearing (Lewis lung carcinoma [LLC1] or CT26) mice for 5 weeks and 16 days, respectively. Body weight, grip strength, inverted hanging time, and muscle weight were assessed. Histological analysis was also performed to assess the effects of GRd. The evolutionary chemical binding similarity (ECBS) approach, molecular docking, Biacore assay, and signal transducer and activator of transcription (STAT) 3 reporter assay were used to identify targets of GRd.Results: GRd significantly induced hypertrophy in the C2C12 and HSkM myotubes (average diameter 50.8 ± 2.6% and 49.9% ± 3.7% higher at 100 nM, vs. control, P ≤ 0.001). GRd treatment ameliorated aging‐ and cancer‐induced (LLC1 or CT26) muscle atrophy in mice, which was evidenced by significant increases in grip strength, hanging time, muscle mass, and muscle tissue cross‐sectional area (1.3‐fold to 4.6‐fold, vs. vehicle, P ≤ 0.05; P ≤ 0.01; P ≤ 0.001). STAT3 was found to be a possible target of GRd by the ECBS approach and molecular docking assay. Validation of direct interaction between GRd and STAT3 was confirmed through Biacore analysis. GRd also inhibited STAT3 phosphorylation and STAT3 reporter activity, which led to the inhibition of STAT3 nuclear translocation and the suppression of downstream targets of STAT3, such as atrogin‐1, muscle‐specific RING finger protein (MuRF‐1), and myostatin (MSTN) (29.0 ± 11.2% to 84.3 ± 30.5%, vs. vehicle, P ≤ 0.05; P ≤ 0.01; P ≤ 0.001). Additionally, GRd scavenged ROS (91.7 ± 1.4% reduction at 1 nM, vs. vehicle, P ≤ 0.001), inhibited TNF‐α‐induced dysregulation of ROS level, and improved mitochondrial integrity (P ≤ 0.05; P ≤ 0.01; P ≤ 0.001).Conclusions: GRd ameliorates aging‐ and cancer‐induced muscle wasting. Our findings suggest that GRd may be a novel therapeutic agent or adjuvant for reversing muscle wasting.


  • Open Access

    Amelioration of muscle wasting by gintonin in cancer cachexia

    by Yoseph Toni Wijaya, Tania Setiawan, Ita Novita Sari, Seung-Yeol Nah, Hyog Young Kwon


  • Top Cited Papers
    Open Access

    Metabolism and function of polyamines in cancer progression

    by Ita Novita Sari, Tania Setiawan, Kwang Seock Kim, Yoseph Toni Wijaya, Kae Won Cho, Hyog Young Kwon